Horizon Pharma AG
Records under this name other than patents Horizon Pharma AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Horizon Pharma AG
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,920,838 | Delayed-release glucocorticoid treatment of rheumatoid disease Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,504,699 | Delayed-release glucocorticoid treatment of rheumatoid disease Formerly held In force · USPTO record | In force | USPTO record | |
| US 6,936,695 | Manufacture and expression of large structural genes Term ended Term ended Aug 30, 2022 · USPTO record | Term ended | Term ended Aug 30, 2022 | USPTO record |
| US 6,488,960 | Corticosteroid formulation Formerly held Term ended Term ended Sep 13, 2021 · USPTO record | Term ended | Term ended Sep 13, 2021 | USPTO record |
| US 6,677,326 | Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration Formerly held Term ended Ended no later than Sep 13, 2021 · USPTO record | Term ended | Ended no later than Sep 13, 2021 | USPTO record |
| US 6,936,694 | Manufacture and expression of large structural genes Surrendered on reissue Surrendered on reissue Sep 4, 2007 · USPTO record | Surrendered on reissue | Surrendered on reissue Sep 4, 2007 | USPTO record |
| US RE39,821 | Manufacture and Expression of Large Structural Genes Term ended Term ended May 6, 2002 · Low confidence | Term ended | Term ended May 6, 2002 | Low confidence |